Residual Disease after Neoadjuvant Therapy - Developing Drugs for High-Risk Early Breast Cancer

N Engl J Med. 2019 Feb 14;380(7):612-615. doi: 10.1056/NEJMp1900079.

Authors

Tatiana M Prowell¹, Julia A Beaver¹, Richard Pazdur¹

Affiliation

¹ From the Office of Hematology and Oncology Products, Center for Drug Evaluation and Research (T.M.P., J.A.B.), and the Oncology Center of Excellence (R.P.), Food and Drug Administration, Silver Spring, and the Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore (T.M.P., J.A.B.) - both in Maryland.

PMID: 30763188
DOI: 10.1056/NEJMp1900079

No abstract available

MeSH terms

Antineoplastic Agents / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology
Breast Neoplasms / therapy
Female
Humans
Neoadjuvant Therapy
Neoplasm Staging
Neoplasm, Residual
Receptor, ErbB-2 / analysis
Risk Factors
Survival Analysis

Substances

Antineoplastic Agents
ERBB2 protein, human
Receptor, ErbB-2